US 12,070,505 B2
Targeted peptide-drug conjugates
Saghar Mozaffari, Orange, CA (US); David Salehi, Orange, CA (US); Parvin Mahdipoor, Orange, CA (US); Rakesh Tiwari, Orange, CA (US); Hamidreza Montazeri Aliabadi, Rancho Santa Margarita, CA (US); Keykavous Parang, Irvine, CA (US); and Khalid Zoghebi, Orange, CA (US)
Assigned to Chapman University, Orange, CA (US)
Filed by Chapman University, Orange, CA (US)
Filed on Feb. 16, 2022, as Appl. No. 17/673,519.
Claims priority of provisional application 63/149,771, filed on Feb. 16, 2021.
Prior Publication US 2022/0265839 A1, Aug. 25, 2022
Int. Cl. A61P 35/00 (2006.01); A61K 31/704 (2006.01); A61K 47/64 (2017.01)
CPC A61K 47/64 (2017.08) [A61K 31/704 (2013.01); A61P 35/00 (2018.01)] 6 Claims
 
1. A drug delivery system comprising a peptide targeting agent conjugated to a pharmaceutical agent,
wherein the peptide targeting agent is a cyclic or hybrid cyclic linear peptide comprising tryptophan (W), arginine (R), and lysine (K) residues; and wherein the peptide targeting agent comprises,

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry